This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pfizer (PFE) Gets FDA Nod for Migraine Nasal Spray Zavzpret
by Zacks Equity Research
Zavzpret (zavegepant) is now part of Pfizer's (PFE) migraine drugs portfolio with the 2022 acquisition of Biohaven. Zavzpret provides migraine patients access to a fast-acting pain-relief option.
Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how BioLife Solutions, Inc. (BLFS) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.
Vertex (VRTX) to Begin Clinical Study on Type I Diabetes Drug
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) receives FDA clearance to begin clinical development of VX-264, which has the potential to treat type I diabetes.
Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate
by Zacks Equity Research
Trevena (TRVN) has initiated proof-of-concept study to evaluate TRV045 as a potential treatment for epilepsy and other CNS disorders.
BioMarin (BMRN) Provides FDA Filing Update for Gene Therapies
by Zacks Equity Research
The FDA accepts BioMarin's (BMRN) label-expansion filing for Voxzogo to treat children under five years with achondroplasia. The agency extends the review period for Roctavian BLA.
Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review
by Zacks Equity Research
Sanofi's (SNY) sBLA seeking label expansion of drug Dupixent for chronic spontaneous urticaria accepted by the FDA
KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus
by Zacks Equity Research
Kala's Q4 earnings miss estimates. Its shares rise in pre-market trading on Mar 6.
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top
by Zacks Equity Research
Puma Biotechnology's (PBYI) Q4 2022 loss is wider than estimates, Revenues beat the same.
Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amarin Corporation's (AMRN) fourth-quarter 2022 earnings and revenues beat estimates; Vascepa sales decline.
Axsome (AXSM) Q4 Earnings Miss, Auvelity Records First Sales
by Zacks Equity Research
Axsome Therapeutics (AXSM) incurs wider-than-expected loss in Q4 2022. Revenues beat estimates while shares gain.
Theravance's (TBPH) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Thervance's (TBPH) fourth-quarter loss wider than expected. Revenues decline year over year.
What Makes CRISPR Therapeutics AG (CRSP) a New Buy Stock
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has CRISPR Therapeutics (CRSP) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how CRISPR Therapeutics AG (CRSP) and Applied Molecular Transport Inc. (AMTI) have performed compared to their sector so far this year.
CRISPR (CRSP) Q4 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) fourth-quarter 2022 loss is narrower than expected, while sales miss estimates.
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 39.22% and 99.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $50.87 in the latest trading session, marking a -1.24% move from the prior day.
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors' focus will be on CRISPR Therapeutics' (CRSP) pipeline, specifically its lead candidate exa-cel, in its fourth-quarter earnings.
Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) four-quarter 2022 earnings and sales beat estimates. VRTX also issues better-than-expected revenue guidance for 2023.
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $55.27 in the latest trading session, marking a -1.51% move from the prior day.
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex Pharmaceuticals' (VRTX) Q4 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.
Strength Seen in CRISPR Therapeutics AG (CRSP): Can Its 7.2% Jump Turn into More Strength?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $50.47, moving -0.55% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.96, moving +1.25% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.94, marking a +0.56% move from the previous day.
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $46.68, moving -1.12% from the previous trading session.